Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection.

ABSTRACT:

Introduction

Clostridium difficile infection (CDI) is a common cause of nosocomial diarrhea. Metronidazole and vancomycin are the primary treatment options for CDI, but increasing rates of antimicrobial resistance and severe, refractory disease have prompted the need for alternative agents. Tigecycline has previously demonstrated favorable in vitro activity against C. difficile isolates, but clinical data on its use in the treatment of CDI are severely lacking. The objective of this study was to describe our experience using tigecycline in the treatment of severe and severe complicated CDI.

Methods

This was a retrospective case series of hospitalized patients with severe and severe complicated CDI who were treated with tigecycline. Disease severity assessments were determine

SUBMITTER: Britt NS 

PROVIDER: S-EPMC4269622 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature